 Juri Boguniewicz
Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Communicable Diseases | 2 | 2023 | 159 | 1.390 |
Why?
| | Phaeohyphomycosis | 1 | 2022 | 1 | 0.790 |
Why?
| | Cerebral Ventriculitis | 1 | 2022 | 4 | 0.790 |
Why?
| | Central Nervous System Infections | 1 | 2022 | 35 | 0.750 |
Why?
| | Enterobacter | 1 | 2021 | 8 | 0.740 |
Why?
| | Adenosine Monophosphate | 1 | 2022 | 66 | 0.720 |
Why?
| | Enterobacteriaceae Infections | 1 | 2021 | 43 | 0.710 |
Why?
| | Alanine | 1 | 2022 | 152 | 0.700 |
Why?
| | Fellowships and Scholarships | 2 | 2025 | 306 | 0.700 |
Why?
| | Immunocompromised Host | 1 | 2022 | 202 | 0.660 |
Why?
| | Bone Diseases, Infectious | 1 | 2019 | 8 | 0.640 |
Why?
| | Myositis | 1 | 2019 | 52 | 0.620 |
Why?
| | Salmonella | 1 | 2019 | 62 | 0.610 |
Why?
| | Bacteremia | 1 | 2021 | 214 | 0.610 |
Why?
| | Salmonella Infections | 1 | 2019 | 57 | 0.610 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 539 | 0.600 |
Why?
| | Arthritis | 1 | 2019 | 95 | 0.600 |
Why?
| | Sepsis | 2 | 2023 | 617 | 0.590 |
Why?
| | Antiviral Agents | 3 | 2024 | 744 | 0.560 |
Why?
| | Staphylococcus aureus | 3 | 2025 | 450 | 0.550 |
Why?
| | Dermatitis, Atopic | 3 | 2025 | 329 | 0.470 |
Why?
| | Staphylococcal Infections | 1 | 2019 | 400 | 0.450 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 1809 | 0.380 |
Why?
| | Child | 13 | 2024 | 21935 | 0.290 |
Why?
| | Haemophilus influenzae | 2 | 2024 | 63 | 0.260 |
Why?
| | Hearing Loss, Sensorineural | 2 | 2024 | 67 | 0.250 |
Why?
| | Hearing Loss | 3 | 2024 | 221 | 0.250 |
Why?
| | Infectious Disease Medicine | 1 | 2025 | 13 | 0.240 |
Why?
| | Needs Assessment | 2 | 2025 | 376 | 0.230 |
Why?
| | Certification | 1 | 2025 | 113 | 0.220 |
Why?
| | Meningitis, Haemophilus | 1 | 2023 | 6 | 0.210 |
Why?
| | Haemophilus Infections | 1 | 2024 | 42 | 0.210 |
Why?
| | Meningitis, Bacterial | 1 | 2024 | 47 | 0.210 |
Why?
| | Meningitis, Pneumococcal | 1 | 2023 | 7 | 0.200 |
Why?
| | Lymphopenia | 1 | 2023 | 62 | 0.200 |
Why?
| | Anti-Infective Agents, Local | 1 | 2023 | 40 | 0.200 |
Why?
| | Neutropenia | 1 | 2023 | 146 | 0.200 |
Why?
| | Amphotericin B | 1 | 2022 | 31 | 0.200 |
Why?
| | Faculty | 1 | 2023 | 147 | 0.190 |
Why?
| | Infant | 6 | 2024 | 9465 | 0.190 |
Why?
| | Educational Measurement | 1 | 2025 | 289 | 0.190 |
Why?
| | Ascomycota | 1 | 2022 | 31 | 0.190 |
Why?
| | Deafness | 1 | 2023 | 77 | 0.190 |
Why?
| | Humans | 22 | 2025 | 137585 | 0.190 |
Why?
| | Antifungal Agents | 1 | 2022 | 136 | 0.180 |
Why?
| | Career Choice | 1 | 2023 | 219 | 0.180 |
Why?
| | Cytomegalovirus Infections | 1 | 2023 | 192 | 0.180 |
Why?
| | Mentors | 1 | 2023 | 202 | 0.180 |
Why?
| | Metagenomics | 1 | 2022 | 169 | 0.180 |
Why?
| | Plasma | 1 | 2022 | 212 | 0.170 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 80 | 0.170 |
Why?
| | Bacterial Infections | 1 | 2023 | 250 | 0.170 |
Why?
| | Shock, Septic | 1 | 2023 | 219 | 0.170 |
Why?
| | Disease Management | 2 | 2022 | 628 | 0.170 |
Why?
| | Central Nervous System | 1 | 2022 | 258 | 0.170 |
Why?
| | Child, Preschool | 5 | 2024 | 11074 | 0.170 |
Why?
| | Adolescent | 6 | 2024 | 21513 | 0.160 |
Why?
| | Organ Transplantation | 1 | 2023 | 250 | 0.160 |
Why?
| | Anti-Infective Agents | 1 | 2023 | 255 | 0.160 |
Why?
| | Thyroiditis, Suppurative | 1 | 2019 | 1 | 0.160 |
Why?
| | Candida tropicalis | 1 | 2019 | 4 | 0.160 |
Why?
| | Thyroid Crisis | 1 | 2019 | 8 | 0.160 |
Why?
| | Candidiasis | 1 | 2019 | 56 | 0.160 |
Why?
| | Hospitals, Pediatric | 2 | 2020 | 508 | 0.160 |
Why?
| | Advisory Committees | 1 | 2020 | 219 | 0.150 |
Why?
| | Bone Diseases | 1 | 2019 | 62 | 0.150 |
Why?
| | Cross Infection | 1 | 2021 | 256 | 0.150 |
Why?
| | Texas | 1 | 2019 | 244 | 0.150 |
Why?
| | Antimicrobial Stewardship | 1 | 2020 | 118 | 0.150 |
Why?
| | Risk Factors | 3 | 2024 | 10388 | 0.150 |
Why?
| | Databases, Factual | 1 | 2024 | 1357 | 0.140 |
Why?
| | Sensitivity and Specificity | 1 | 2022 | 1946 | 0.140 |
Why?
| | Pediatrics | 1 | 2025 | 1101 | 0.130 |
Why?
| | Female | 8 | 2024 | 73304 | 0.120 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 289 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2023 | 3556 | 0.120 |
Why?
| | Retrospective Studies | 5 | 2024 | 15657 | 0.110 |
Why?
| | Bile Ducts | 1 | 2014 | 71 | 0.110 |
Why?
| | Biliary Atresia | 1 | 2014 | 163 | 0.100 |
Why?
| | Hospitalization | 1 | 2022 | 2199 | 0.090 |
Why?
| | Male | 7 | 2024 | 67762 | 0.080 |
Why?
| | Immunoglobulin G | 1 | 2014 | 893 | 0.080 |
Why?
| | Skin | 2 | 2025 | 752 | 0.080 |
Why?
| | Polysaccharides, Bacterial | 1 | 2008 | 70 | 0.070 |
Why?
| | Respiratory Sounds | 1 | 2008 | 125 | 0.070 |
Why?
| | Drug Resistance | 1 | 2007 | 169 | 0.070 |
Why?
| | Bronchi | 1 | 2007 | 260 | 0.060 |
Why?
| | Bronchodilator Agents | 1 | 2007 | 252 | 0.060 |
Why?
| | Young Adult | 1 | 2021 | 13209 | 0.060 |
Why?
| | Asthma | 2 | 2008 | 2295 | 0.060 |
Why?
| | Hearing Loss, Bilateral | 1 | 2023 | 12 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2007 | 565 | 0.050 |
Why?
| | Body Surface Area | 1 | 2023 | 34 | 0.050 |
Why?
| | Ganciclovir | 1 | 2023 | 53 | 0.050 |
Why?
| | Animals | 3 | 2025 | 36940 | 0.050 |
Why?
| | Vaccines, Conjugate | 1 | 2023 | 65 | 0.050 |
Why?
| | Inflammation | 1 | 2014 | 2837 | 0.050 |
Why?
| | Steroids | 1 | 2023 | 167 | 0.050 |
Why?
| | Neutrophils | 1 | 2008 | 1238 | 0.050 |
Why?
| | Cytomegalovirus | 1 | 2023 | 157 | 0.050 |
Why?
| | Hearing | 1 | 2023 | 118 | 0.050 |
Why?
| | Pneumococcal Vaccines | 1 | 2023 | 142 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2023 | 169 | 0.040 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2023 | 233 | 0.040 |
Why?
| | Adult | 2 | 2021 | 37929 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2020 | 170 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 96 | 0.040 |
Why?
| | Thyroidectomy | 1 | 2019 | 106 | 0.040 |
Why?
| | Body Weight | 1 | 2023 | 985 | 0.040 |
Why?
| | Infection Control | 1 | 2020 | 167 | 0.040 |
Why?
| | Dysbiosis | 1 | 2020 | 181 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 347 | 0.040 |
Why?
| | Information Dissemination | 1 | 2020 | 218 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2020 | 283 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 411 | 0.030 |
Why?
| | Program Evaluation | 1 | 2020 | 898 | 0.030 |
Why?
| | Prevalence | 1 | 2023 | 2734 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2008 | 652 | 0.030 |
Why?
| | Rotavirus | 1 | 2014 | 20 | 0.030 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 39 | 0.030 |
Why?
| | Bilirubin | 1 | 2014 | 97 | 0.030 |
Why?
| | Albumins | 1 | 2014 | 114 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2014 | 132 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3284 | 0.020 |
Why?
| | Interleukin-2 | 1 | 2014 | 455 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2025 | 5778 | 0.020 |
Why?
| | Quality Improvement | 1 | 2020 | 1178 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2014 | 789 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4565 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 4149 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1242 | 0.020 |
Why?
| | United States | 1 | 2025 | 14841 | 0.020 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 26 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 1091 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2014 | 900 | 0.020 |
Why?
| | Leukocyte Elastase | 1 | 2007 | 76 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2007 | 132 | 0.020 |
Why?
| | Spirometry | 1 | 2007 | 281 | 0.020 |
Why?
| | Dexamethasone | 1 | 2007 | 368 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2019 | 10811 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 545 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4295 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2833 | 0.010 |
Why?
| | Mice | 1 | 2014 | 17787 | 0.010 |
Why?
| | Middle Aged | 1 | 2007 | 33479 | 0.000 |
Why?
|
|
Boguniewicz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|